Table 2.
Characteristics of patients treated on the active disease arm, with any measurable disease before infusion
| ID | Donor | DL | Age/sex | Disease | Prior treatments | Donor chimerisms (blood or marrow) | Ongoing tacrolimus on day of infusion |
|---|---|---|---|---|---|---|---|
| A2 | MRD | 1 | 70/M | IDH1mut | 7+3→decitabine→IDH inhibitor→cutis relapse→CIA→RIC-HCT→relapse | 100% (skin relapse) | No |
| A3 | Haplo | 1 | 16/M | MDS→AML | Double cord HCT→AML relapse→C→haplo-HCT×2→relapse | <20% | No |
| 1 & A1* | MRD | 1 | 57/F | FLT3-ITD | CIA→sorafenib→CIA×2→RIC-HCT→mLST→steroids→relapse | 100% (bone relapse) | No |
| A4 | MRD | 2 | 55/M | PIF | 7+3→HiDAC×4→RIC-HCT→relapse→DLI×4→MEC→5-aza→relapse | Not checked | No |
| A5* | Haplo | 2 | 23/M | Del 17p | CIA×3→haplo-HCT→relapse→CIA-decitabine→haplo-HCT→5-aza→nivolumab→CD123 BiTE→MEC-decitabine→ midostaurin→relapse | Not checked | No |
| A5* | Haplo | 2 | 23/M | Del 17p | CIA×3→ haplo-HCT#1→relapse→ CIA-decitabine→haplo-HCT#2→5-aza→nivolumab→CD123 BiTE→MEC-decitabine→midostaurin→relapse→mLST→haplo-HCT#3→relapse | Not checked | No |
| A6* | MRD | 3 | 20/F | FLT3-ITD | 7+3→HiDAC→MAC-HCT→relapse→CIA→relapse | 45% | No |
| A6* | MRD | 3 | 20/F | FLT3-ITD | 7+3→HiDAC→MAC-HCT→relapse→CIA→relapse→mLST→CIA+decitabine→mLST | Not checked | No |
5-aza, 5 azacytidine; 7+3, 7 d of cytarabine infusion and 3 d of idarubicin; CD123 BiTE, CD123-CD3 bispecific T-cell engager on an investigational protocol; CIA, clofarabine, idarubicin, and cytarabine; del 17p, deletion of short arm of chromosome 17; F, female; FLT3-ITD, fms-like tyrosine kinase 3 receptor-internal tandem duplication; Haplo, haploidentical; HiDAC, high dose (>1 g/m2 cytarabine); ID, patient ID number; IDHmut, IDH mutation; M, male; MAC, fully myeloablative pre-HCT conditioning chemotherapy; MEC, mitoxantrone, etoposide, and cytarabine; PIF, primary induction failure; RIC, reduced-intensity pre-HCT conditioning chemotherapy.
Reenrolled into the active arm after relapse.